Benzinga | Jul 14, 2020 06:02AM EDT

SunTrust Robinson Humphrey Initiates Coverage On CRISPR Therapeutics with Buy Rating, Announces Price Target of $140

SunTrust Robinson Humphrey analyst Joon Lee initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Buy rating and announces Price Target of $140.